Panellist: Investment Panel 10.00am Day One

Katya Smirnyagina joined Alta in 2002 and focuses on European investment opportunities. She currently represents Alta on the board of directors of Cerenis Therapeutics and Kiadis Pharma. She also led Alta’s investment in Ablynx.

Prior to joining Alta, she worked in business development and finance at Genset, a French genomics-based biotechnology company, where she negotiated a number of licensing agreements and strategic partnerships. Prior to Genset, Katya was a manager with the Mitchell Madison Group, a global management-consulting firm, from 1997 to 2000.

She obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor of Science in Biochemistry with high honors from Moscow University in Russia. Katya completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. She has co-authored a number of scientific papers.

Panellist: Oncology Investment Panel 12.00am Day One

Nicholas Adams was appointed Vice President of Business Development of Antisoma in November 2003. Prior to this he was Business Development Manager of Antisoma for four years where he established significant development collaborations. Nicholas led the out-licensing of Antisoma’s lead product, ASA404, to Novartis and the divestment of Oforta to sanofi-aventis US.

Prior to joining Antisoma, Nicholas held clinical development positions at Ciba-Geigy, Eisai Ltd and Cephalon Inc. Nicholas has a degree in Biology and studied at the College of Law, London.

He is on the organising committee of the Pharma Licensing Group UK.

Panellist: Platform technologies and Novel Therapeutics 16.30pm Day One

Dr Harren Jhoti is Chief Executive of Astex Therapeutics, a clinical-stage UK biotechnology company with around 75 employees that has raised over £80M in private financing from leading European and US venture capital firms. Astex has also established several high profile alliances with pharma companies such as GSK, J&J & Novartis. Dr. Jhoti’s publications include research papers in leading journals such as Nature and Science and Dr. Jhoti has also featured in TIME magazine after being named by the World Economic Forum as a Technology Pioneer. He was also named by the Royal Society of Chemistry as ‘Chemistry World Entrepreneur of the Year’ for 2007. Before setting-up Astex in 1999, he was previously Head of Structural Biology and Bioinformatics at GlaxoWellcome in the UK (1991-1999). While at GlaxoWellcome, he was involved in drug discovery projects aimed at a variety of therapeutic targets in inflammation, cardiovascular, anti-infectives and metabolic diseases.

Panellist: Oncology Investment Panel 12.00pm Day One

Prof Juergen Engel is President & CEO of Æterna Zentaris Inc., formerly CEO of Zentaris AG and Head of Global R&D at ASTA Medica AG (Degussa AG). Adjunct full professor University of Regensburg, honorary professor Technical University of Dresden. Successful development of drugs in oncology, allergy and CNS. Recipient Prix Galien Germany 1995.

Panellist: Investment Panel 10.00am Day One

Regina Hodits is a Venture Partner in the Life Sciences group. She joined Atlas Venture in 2004 and focuses on investments across Europe.

She began her career in venture capital in 2000 with Apax Partners in Munich, where she was responsible for life science investments and was closely involved with Apax’ investments in Genmab, Silence Therapeutics, Astex and Wilex. Prior to Apax Partners, she was an industry specialist for pharmaceutical and biotech companies at McKinsey & Company focusing on building new businesses, spin-offs and mergers in the sector.

Regina currently serves on the Boards of Atlas portfolio companies Fibrex, f-star, Jenavalve and Bicycle Therapeutics where she was founding investor. In addition, she sits on the Boards of Atlas portfolio companies Egalet, Lumavita, NovaMed and ProtAffin. She is an external director at GlaxoSmithKline (GSK) Respiratory CEDD.

Regina was also on the Board of U3 Pharma which was acquired by Daiichi Sankyo Co., Ltd. in 2008.

Regina holds a Ph.D. in Biochemistry, a Master of Science from the Technical University in Vienna, Austria and she completed her post-doctoral research at the MRC in Cambridge, UK. She has been the recipient of a number of scientific awards and research grants, and has published in several journals, including Nature Biotech and JBC.

Panellist: How to ally with Big Pharma 09.00pm Day Two

Nils Debus studied microbiology and biochemistry and holds a PhD in embryonic stem cell research. He started his industry career at Schering AG, Berlin, Germany, heading a research team in diagnostic imaging. Nils has more than fifteen years experience in the pharmaceutical industry, including more than nine years in licensing and business development roles for Schering AG, now Bayer Schering Pharma AG. He has been responsible for identifying, negotiating and closing numerous deals, including product and technology licenses, patent licenses and alliances. Five years ago Nils took over the local Business Development position of the Schering AG research subsidiary Berlex Biosciences in Richmond, California. After the acquisition of Schering by Bayer he was responsible for the licensing of new drug discovery opportunities for Bayer Healthcare Pharmaceuticals in the United States. Nils is now back to the headquarters in Berlin and in charge of the licensing for Hemophilia / Cardiology early stage products and the Global Biologics R&D functions both in Europe and the US.

Panellist: Public Markets and M&A Panel 09.20am Day One

Eric Bernhardt is head of the Healthcare segment and Lead Portfolio Manager of the BB Healthcare (Lux) Fund. Since 1997 Eric has been managing funds in the healthcare, biotechnology and generics sectors for Clariden Leu and Julius Baer Asset Management. Prior experience encompass positions as a pharmaceutical analyst and portfolio manager at UBS. Eric obtained his degree in forest engineering from the Swiss Federal Institute of Technology (ETH) in Zurich and is a CFA chartholder.

Panellist: Public Markets and M&A Panel 09.20am Day One

Rudi Pauwels is a scientist-entrepreneur who completed his PhD in Pharmaceutical Sciences (1990) at the Rega Institute for Medical Research (University of Leuven) in Belgium and is (co-)author of more than 150 publications in peer reviewed journals. He received several awards for his scientific and entrepreneurial initiatives and serves on the Board of several companies and research Institutes.

Rudi founded and built three successful Biotechnology companies: Tibotec, Virco and Galapagos Genomics. His research as well as his entrepreneurial career is driven by medical needs for which he tries to find innovative solutions. He is a strong believer in the value of a multi-disciplinary scientific, technological and clinical approach to solve key pharmaceutical and diagnostic challenges. He executes his plans with the help of carefully selected people who are also motivated 'to make a difference'.

Following a 3 year sabbatical at the Swiss Federal Institute of Technology-EPFL (Lausanne, Switzerland) where he became more familiar with the advances in micro- & nanotechnologies, Rudi took the initiative to create Biocartis to address new needs in the field of diagnostics.

Panellist: Medtech Investment Panel 10.45am Day Two

Crispin Simon is Chief Executive Officer of Biocompatibles International Plc. Crispin Simon joined the company in June 1998. After working at NM Rothschild and McKinsey & Company, he gained general management experience at senior executive level with Rexam plc (then Bowater) and then as President of the Endoscopy Division of Smith & Nephew plc, based in Boston, USA. Crispin Simon is a non-executive Director of Imperial Collage Healthcare NHS Trust and a Governor of Port Regis School. Crispin has a BA in Politics and Economics, Oxford University

Panellist: Medtech Investment Panel 10.45am Day Two

Dr. Markus Hosang is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a VP and CSO of Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee.

He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Avontec GmbH, Okairos AG and Suppremol GmbH. Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), IDEA and Atugen. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.

Panellist: Corporate Investment Panel 11.15am Day One

Ilka Wicke joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. She later joined the Corporate Licensing Division of Boehringer Ingelheim where she over the last 10 years gained extensive experience in the evaluation, negotiation and the management of global licensing transactions. Subsequently Ilka joined the Corporate Licensing group as head of the business advisory teams for oncology, urology and metabolism where she was responsible for the identification and evaluation of pre-clinical and clinical licensing opportunities as well as structuring and negotiating technology and licensing agreements. She later joined the transaction group of Corporate Licensing where she was responsible for the negotiation and conclusion of a variety of global licensing agreements. Ilka has a PhD in organic chemistry from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she spent a year as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches to stimulate antitumour responses.

Chair: CNS & Neurology Panel 17.30pm Day One

Lubor Gaal is Executive Director, Strategic Transactions Group at Bristol-Myers Squibb Company, responsible for pharmaceutical or biotechnology companies in Europe and licensing or acquisition of compounds or drug programs in Neurosciences.

Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d and CBO of Vectron Therapeutics AG. In the US, Lubor was at Berlex Laboratories where he was responsible for Cardiovascular and CNS Licensing of Schering AG. Before joining Berlex, he worked for Burrill and Company, where he advised biotechnology and pharmaceutical companies on business development strategies and execution.

Lubor received his Ph.D. in Molecular and Cell Biology from the University of California at Berkeley and his B.Sc. in Neuroscience from the University of Sussex in Brighton, U.K.

Panellist: Oncology Investment Panel 12.00pm Day One

Patrick J Mahaffy is a founder of Clovis Oncology and has served as its President and Chief Executive Officer and a member of its board of directors since its inception. Previously, Mr. Mahaffy served in the same role at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Mr. Mahaffy was a Vice President at E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the boards of directors of Orexigen Therapeutics, Inc., and Flexion Therapeutics, Inc. He is also a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University.

Chair: Public Markets and M&A Panel 09.20am Day One

Stephanie Léouzon is a Senior Advisor in Credit Suisse’s Investment Banking Division, focusing on European Health Care clients.

She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology, pharmaceutical and speciality pharmaceutical sectors.

She has advised clients on a number of strategic transactions, valued at over $70 billion, and she has been involved in financing transactions to provide over $7 billion to healthcare clients.

Prior to joining Credit Suisse in 1998, Stephanie’s experience included working in Health Care at Lehman Brothers, JP Morgan and Salomon Brothers (now Citigroup). Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.

Panellist: Public Markets and M&A Panel 09.20am Day One

Chris Britten leads the Life Science sector Advisory team within Deloitte Corporate Finance based in London.

Prior to joining Deloitte, Chris spent 15 years at GlaxoSmithKline (GSK), one of the world's leading research-based pharmaceutical and healthcare companies, spending time in R&D, Corporate Venturing and latterly in Worldwide Business Development. He has a scientific background, a PhD in biochemistry and an MBA. Chris has gained huge experience and contacts in the Life Sciences market having negotiated a variety of acquisitions, licences, divestments and strategic alliances with partners around the world.

Current activities include advising clients across the spectrum of the Life Science sector, from molecular diagnostics to biotechnology, generics to specialty pharmaceuticals and OTC products.

Panellist: Platform Technologies and Novel Therapeutics 16.30pm Day One

Martin Williams has twenty three years of experience in the global biopharmaceutical business. He has closed over $3 billion worth of corporate transactions, including partnerships, M&A, and public and private financings. He joined Dicerna from Synta Pharmaceuticals, where he was Chief Business Officer and SVP for Commercial and Business Development, with responsibility for corporate development, sales & marketing, corporate communications and medical affairs. There, he helped the company complete its IPO in 2007 and negotiated a $1 billion collaboration with GlaxoSmithKline for its lead oncology product. Prior to joining Synta, Martin was Head of Corporate Development for Altus Pharmaceuticals, where he led all strategic partnering activities. Before joining Altus, he was Senior Vice President, Corporate Development and Marketing at Oscient Pharmaceuticals. Martin held various leadership positions and directed the development, commercialization and launch of several flagship brands for Glaxo, Hoffmann-La Roche, American Cyanamid and Wyeth. These brands included Glaxo's blockbuster Zantac® and Zofran®; Hoffmann La-Roche's Xenical®; and Lederle/Wyeth's global anti-infective portfolio, including Zosyn®/Tazocin®. He holds an MBA from Harvard Business School, an MS from the University of Manchester, England, and a BA in biology from the University of Humberside, Hull, England.

Panellist: CNS and Neurology Panel 17.30pm Day One

Jakob Knudsen serves as Chief Commercial Officer of Egalet overseeing partnering, financing and IP. He was previously heading the Corporate Business Development function at ALK-Abelló A/S, a Danish biopharmaceutical company, he has also held responsibility for various sales and marketing functions within ALK.

Jakob holds an LL.M. from the university of Copenhagen and he trained with the law-firm Arup & Hvidt in Copenhagen. He also holds an MBA from Imperial College, UK.

Chair: CNS & Neurology Panel 17.30am Day One

Lorenza Castellón is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations.

Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work.

Chair: Oncology Investment Panel 12.00pm Day One

Christina Takke was appointed Partner at Forbion Capital Partners in 2010 and she joined the group (previously ABN AMRO Capital Life Sciences) in 2000. At Forbion, Dr. Takke is responsible for scouting and the analysis of new investment opportunities as well as the general deal execution. She has been instrumental in the financing of several Forbion portfolio companies and led the investment in arGEN-X. She serves on the supervisory board of arGEN-X BV (The Netherlands), Pieris AG (Germany), Bioceros BV (The Netherlands) and was closely involved with GlycArt (Switzerland) as an observer prior to its sale to Roche in 2005. Before joining ABM AMRO in 2000, she worked with Bio-Gen-Tec-NRW, a regional development organization for the biotechnology industry, which was based in Cologne, Germany. Dr. Takke began her scientific career with a master's degree in biology from the Technical University of Darmstadt. She subsequently joined the group of Prof Dr, Campos-Ortega at the Institute of Development Biology of the University of Cologne, where she studied the Delta-Notch signaling pathway and its role during zebra fish neurogenesis and early somite development.

Panellist: Medtech Investment Panel 10.45am Day Two

Arthur Franken joined Gilde in 2001. Mr. Franken led the investments in Conatus Pharmaceuticals, FlowCardia (acquired by C. R. Bard, Inc. (NYSE: BCR)) and MTM Laboratories. He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, AMT (IPO on Euronext), BG Medicine, IDEA, Neuro3D (acquired by Evotec) and Pieris.

Mr Franken represents Gilde on the board of MTM Laboratories. He served as a board member for FlowCardia (acquired by C. R. Bard, Inc. (NYSE: BCR)) and observed on the boards of Agendia and AMT (IPO on Euronext).

Prior to joining Gilde Mr. Franken gained experience in cardiovascular research at TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. During his degree, Mr Franken specialized in molecular toxicology at the departments of Toxicology and Biopharmacy in the Leiden/Amsterdam Center for Drug Research. He is a Dutch national.

Panellist: How to ally with a Big Pharma? 09.00am Day Two

Andrew Jefferson is a Global Licensing Director within Roche Partnering based in Basel Switzerland. Andrew leads the negotiation team for partnering opportunities. He has spent 9 years in business development previously holding the position of Global Head of Strategic Evaluations where he led the team responsible for the business assessment of partnering opportunities and project leadership for M&:A transactions. His other roles have included responsibility for business assessment, scouting and evaluation having previously had the positions Global Head Surveillance, Analysis and Valuation and Business Development Director within the Acquisitions and Strategic Alliances department of Roche Partnering. Appointed in 2000 as Business Analyst for the Xenical International Business team, Andrew joined the Roche Partnering in-licensing team in 2001.

Prior to joining Roche, Andrew was at Novartis, UK were he held roles in both manufacturing and marketing functions.

Andrew gained his MBA from The University of Brighton and has a first class honours degree in Chemistry from The University of Nottingham.

Panellist: How to ally with Big Pharma? 09.00am Day Two

Margaret Beer studied at the Universities of Reading and London before carrying out her research work on serotonin pharmacology. She joined Merck, as a bench neuroscientist, in 1984 following her return to the UK from Stanford University. She is one of the founding members of the team responsible for the development of Merck’s anti-migraine drug MAXALT and was involved in the project during the basic research stage through to the launch in 1997. Her other main areas of research interest include depression, anxiety and multiple sclerosis.

Margaret joined Merck's Worldwide Licensing and External Research, Europe, group in 2003. This group was established in 2002 specifically in recognition of the scientific excellence in Europe and the wealth of potential licensing opportunities. Margaret assumed leadership of the group in 2008.

She is the co-author of 100 original research articles, review articles, and abstracts, and has presented widely at international professional meetings.

Chair: Corporate Investment Panel 11.15am Day One

Roel Bulthuis is Head of Merck Serono Ventures, the strategic venture capital group of Merck Serono. Through the ventures group, Merck Serono is committed to actively invest in emerging biotech companies which have the potential to provide innovative products in Merck Serono’s core therapeutic areas, or access to innovative technologies. In addition to the venture fund, Roel is also responsible for all ‘externalization’ transactions at Merck Serono, including ‘fostering’ deals, spin-offs and other alternative financing models. Roel joined Merck Serono in 2006 and is based in Geneva, Switzerland. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before joining Fortis Bank, Roel worked at Devgen NV in Gent, Belgium, as a business analyst. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.

Panellists: Platform Technologies and Novel Therapeutics Panel 16.30pm Day One

Christian Zahnd (Switzerland) is Chief Executive Officer and member of the board of directors of Molecular Partners. After graduating with a master of science from the ETH Zurich and working for Merrill Lynch, Christian Zahnd earned his PhD from the University of Zürich. His main interest was on antibodies and antibody fragments, which he studied in own research and in academic and industry collaborations. Pioneering therapeutic applications of DARPins, he co-founded Molecular Partners and was a member of the management from the early days.

Panellist: Public Markets and M&A Panel 09.20am Day One

Catherine Moukheibir Mrs. Moukheibir (°1959) obtained an MA in Economics and an MBA from Yale University (United States). She is a capital markets specialist with 19 years of financial industry experience in an international environment, including eight years in the pharmaceutical sector. Mrs. Moukheibir began her career as a partner and principal of leading management consulting firms in Boston and London and held the position of Executive Director Investment Banking with both Salomon Smith Barney and Morgan Stanley in London. Before becoming CFO of Movetis, she was Director of Capital Markets at Zeltia SA (Spain) where she also served on the boards of Xylazel SA, Genomica SAU and Sylentis SA, and held, at Sylentis, the position of vice president.

Mrs. Moukheibir has taught at Boston University School of Management (United States) and at ESADE (Spain).

Panellist: CNS and Neurology Panel 17.30pm Day One

Lawrence Bloch has served as NeurAxon, Inc.’s Chief Executive Officer since 2007 raising $41 million in NeurAxon’s Series B financing. From 2004 to 2006 he served as Chief Business Officer and Chief Financial Officer of NitroMed, Inc., raising $150 million in equity and $20 million in debt to support company growth from 40 to 300 employees including an exclusively dedicated contract sales force for the commercial launch of BiDil®. From 2000 to 2004 he served as Chief Financial Officer, and from 1999 to 2002 as Vice President of Business Development, of Applied Molecular Evolution, Inc., leading AME’s $101.6 million IPO to support company growth from 18 to 135 employees and AME’s $420 million merger with Eli Lilly and Company. Dr. Bloch earned a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School and lives in Newton, MA with his wife and three children.

Panellist: How to ally with Big Pharma? 09.00am Day Two

Esteban Pombo-Villar PhD CChem FRSC is Head of Alliance Management at the Novartis Institutes for BioMedical Reasearch (NIBR). His group is responsible for managing research and early development collaborations with academic and biopharmaceutical groups world-wide. Dr Pombo-Villar obtained his PhD in Organic Chemistry from the University of Warwick in the UK. After postdoctoral studies at the ETH in Zurich, he joined Sandoz Neuroscience Research in Basel in 1988, and worked on drug discovery projects as well as leading collaborative projects for investigation of emerging technologies. He was External Collaborations Manager for Neuroscience, and from 2003, was Head of Stategic Alliance Management based in Basel, Switzerland.

Panellist: Investment Panel 10.00am Day One

Dr Reinhold J Ambros was previously Managing Director of the Novartis BioVenture Fund in the USA. At Novartis he worked in Corporate Finance where he held the position of Head of Group Strategic Planning for several years. He was responsible for post merger integrations at Novartis Corporate M & A and was global head BD & L cardiovascular and metabolic diseases at Novartis Pharma. Earlier in his career he had global leadership positions for key drug development projects at Novartis and Roche. He trained as a pharmacist, Ph.D. in medicinal chemistry and pharmacology and focused postdoctoral training in clinical pharmacology. He serves on the boards of Genedata and Symetis in Switzerland and Cylene, MicroCHIPS, Tokai and Forma in the USA.

Panellist: How to ally with Speciality Pharma? 09.00am Day Two

Carlos de Sousa is Vice President Licensing at Nycomed and responsible for the company´s in-licensing activities.

He joined Nycomed February 2009 from Newron Pharmaceuticals SpA in Italy, where he was Chief Business Officer responsible for the company´s growth strategy, including its in- and out-licensing, and mergers & acquisitions activities. Previously, he was Global Head of Business Development and Licensing at Schwarz Pharma AG in Germany. Prior to that Carlos de Sousa served as Head of Global Negotiations Neuroscience and Region Europe Business Franchise Head Respiratory & Dermatology for Novartis Pharma AG, based in Switzerland. In 1989 he started his career in the pharmaceutical industry with Pfizer as Medical Director in Portugal. He then joined the Pfizer Corporation in New York, USA, where he was initially appointed International Medical Director, and subsequently Director Corporate Licensing & Development, and Director Medical and Regulatory Affairs for Latin America.

Panellist: How to ally with Big Pharma? 09.00am Day Two

Alex Chanas is part of the global outreach, evaluation and licensing team within Worldwide Business Development Strategy and Innovation. He has been in his present position since joining Pfizer approximately 13 years ago. Alex is based at Pfizer’s R&D site in Sandwich, UK.

Prior to that he was head of CNS and anti-viral development projects at Astra Pharmaceuticals’ Clinical Research Unit in Edinburgh, where he spent 16 years co-ordinating clinical trials in schizophrenia, depression, stroke and various anti-viral programmes.

Alex originally trained as a virologist at the London School of Hygiene and Tropical Medicine and I have a PhD in Pathology from London University.

Chair: Platform Technologies and Novel Therapeutics 16.30pm Day One
Chair: How to ally with Big Pharma? 09.00am Day Two
Chair: How to ally with Speciality Pharma? 09.00am Day Two

Dr Walton is the Founder and CEO of PharmaVentures. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan (US) and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Although Dr Walton’s main focus is his role as Chief Executive Officer of PharmaVentures, he is available for some consultancy assignments.

Panellist: Platform Technologies and Novel Therapeutics 16.30pm Day One

Hans Chistinger joined Roche in 2007 and is responsible for Biologics Technology in-licensing with a focus on accessing global innovation to maintain Roche’s leadership position in biologics. Examples of recent deals he has been involved with include Aileron Therapeutics, PTC Therapeutics, AdiMab, AnaptysBio. Hans is a member of the Roche Chugai Biologics Steering Group which is focused on sharing biologics technology information and leveraging geographical reach for the two companies.

Additionally, Hans leads negotiations for technology and product in-licensing opportunities outside of the biologics technology area. He leads a joint Roche Genentech team in the implementation of a shared business development application to manage Partnering activities across both organizations.

Hans has been in the biopharmaceutical industry for 19 years and has spent the last 10 years in business development roles supporting R&D portfolios as well as corporate level initiatives in several leading organizations including Roche, Abbott and Vertex. He began his career in the laboratories at Genentech where his work resulted in 15 peer-reviewed publications focusing on structural biology analyses of VEGF, PlGF, APO2L.

Panellist: Corporate Investment Panel 11.15am Day One

Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals. She currently serves as a board observer at Aileron, Alios, Ambit, Ambrx, Conatus, Envoy, Idaho Technology and Nereus. She has a BA from Valparaiso University and a JD from University of Michigan. More information on the Roche Venture Fund can be found at www.venturefund.roche.com.

Panellist: Oncology Investment Panel 12.00pm Day One

Dr Richard Goodfellow has over 30 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s flotation on the London Stock Exchange and successfully negotiated numerous deals.

In addition to co-founding Scancell's ImmunoBody cancer vaccine business, Dr Goodfellow was also a co-founder of Paradigm Therapeutics, a Cambridge based functional genomics company and was a former Director of Enact Pharma plc.

Panellist: Platform Technologies and Novel Therapeutics 16.30pm Day One

Sten Verland's is a partner at Sunstone Capital. He has more than 20 years experience as an international executive, entrepreneur and venture investor in biotech companies as well as pre-clinical and clinical CROs. Dr. Verland has served as non-executive director on sixteen Boards and is currently a non-executive chairman of Action Pharma A/S and Zymenex A/S, and non-executive director of F2G Ltd. Dr. Verland holds a MSc in Biology and a PhD in Immunology.”

Panellist: Oncology Investement Panel 12.00pm Day One

Joanna Horobin MD is President and CEO of Syndax Pharmaceuticals, a privately held company focused on the development of innovative cancer therapies. Formerly Vice President of Oncology at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Chief Operating Officer of CombinatoRx, Inc., Dr. Horobin has more than 25 years of pharmaceutical drug development experience in multiple therapeutic areas, with a focus on oncology and a particular interest in the development of combination strategies.

At Rhone-Poulenc Rorer she led the global oncology business, including directing the successful global launch, and subsequent market expansion, of Taxotere® (docetaxel) and also led a successful joint venture with the Japanese company Chugai, Chugai Rhone-Poulenc, which developed and launched the granulocyte growth factor Granocyte® (lenograstim) for the European market. As Chief Operating Officer at CombinatoRx, a company focused on combination products, she raised over $70 million in private financing, transitioned the company from a discovery-focused start-up to a clinical-stage enterprise, and positioned the company for a successful initial public offering. Dr. Horobin was also Executive Vice President at EntreMed, a company developing angiogenesis inhibitors. She spent a year as Entrepreneur in Residence with the venture capital firm MPM Capital.

Her pharmaceutical experience spans clinical development, marketing, and general management in both public and private companies.

Dr. Horobin qualified in medicine from the Victoria University of Manchester, England, and additionally gained Membership of the Royal College of General Practitioners in the United Kingdom. She holds the Diploma of Pharmaceutical Medicine from the Royal College of Physicians in the United Kingdom.

Panellist: CNS and Neurology Panel 17.30pm Day One

Melanie Lee's academic grounding in molecular genetics in three complex systems of DNA repair and recombination, RNA splicing and cell cycle was a broad and an important foundation for her future career. Melanie was cited by Sir Paul Nurse in his inaugural ceremony in Stockholm on receipt of his Nobel Prize for Medicine in 2001 for her contribution to his cell cycle work. Melanie’s industrial career has been through Glaxo, GlaxoWellcome, Celltech and UCB. During her career leading the discovery organization as well as Research & Development, for 6 years as a Board Director with Celltech plc and 5 years on the Executive Committee of UCB, Melanie has led R&D through 6 integrations. In 2008 she put in place the foundations of an innovative organization named UCB NewMedicines which is accountable from Discovery through to Proof of Concept for small and large molecule drugs. Melanie is the Chair of Cancer Research Technology and Deputy-Chair of Cancer Research UK. Melanie was honoured in 2008 with a CBE for services to Medical Science.

Melanie believes that the pharmaceutical industry is undergoing a complete change of mindset and skills base as well as way of working which enhances the importance of biotech companies for the future of the new drug Research & Development. She believes that the importance of academia and industry (large & small) working together is crucial to innovation and advancing science and human health. Melanie is currently CEO of Syntaxin Ltd which she joined in February 2010.

Panellist: Corporate Investment Panel 11.15am Day One

Dr Graeme Martin is President and CEO of TRI with day-to-day responsibility for operations. He brings more than 28 years of pharmaceutical R&D experience, primarily in multinational Pharmas (Wellcome; Glaxo Wellcome: Hoffman La Roche). He was responsible for the discovery and preclinical development of Zomig®, marketed worldwide for the acute treatment of migraine. More recently, Dr. Martin served as Chief Technical Officer at Telik Inc. with responsibility for technology and business development before establishing a Bay Area biopharmaceutical consulting operation, Discovery-Insight. Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK